These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Long-acting muscarinic antagonists (LAMA) added to combination long-acting beta2-agonists and inhaled corticosteroids (LABA/ICS) versus LABA/ICS for adults with asthma. Kew KM; Dahri K Cochrane Database Syst Rev; 2016 Jan; 2016(1):CD011721. PubMed ID: 26798035 [TBL] [Abstract][Full Text] [Related]
3. Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting β Ferguson GT; Darken P; Ballal S; Siddiqui MK; Singh B; Attri S; Holmgren U; de Nigris E Adv Ther; 2020 Jun; 37(6):2956-2975. PubMed ID: 32335859 [TBL] [Abstract][Full Text] [Related]
4. The effects of single inhaler triple therapy vs single inhaler dual therapy or separate triple therapy for the management of chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomized controlled trials. Lai CC; Chen CH; Lin CYH; Wang CY; Wang YH Int J Chron Obstruct Pulmon Dis; 2019; 14():1539-1548. PubMed ID: 31371939 [TBL] [Abstract][Full Text] [Related]
5. Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD). Horita N; Goto A; Shibata Y; Ota E; Nakashima K; Nagai K; Kaneko T Cochrane Database Syst Rev; 2017 Feb; 2(2):CD012066. PubMed ID: 28185242 [TBL] [Abstract][Full Text] [Related]
6. Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus addition of long-acting beta2-agonists (LABA) for adults with asthma. Kew KM; Evans DJ; Allison DE; Boyter AC Cochrane Database Syst Rev; 2015 Jun; 2015(6):CD011438. PubMed ID: 26031392 [TBL] [Abstract][Full Text] [Related]
7. Open and Closed Triple Inhaler Therapy in Patients with Uncontrolled Asthma. Kotoulas SC; Tsiouprou I; Domvri K; Ntontsi P; Pataka A; Porpodis K Adv Respir Med; 2023 Jul; 91(4):288-300. PubMed ID: 37489386 [TBL] [Abstract][Full Text] [Related]
8. Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying doses of inhaled corticosteroids in adolescents and adults with asthma: a systematic review and network meta-analysis. Oba Y; Anwer S; Maduke T; Patel T; Dias S Cochrane Database Syst Rev; 2022 Dec; 12(12):CD013799. PubMed ID: 36472162 [TBL] [Abstract][Full Text] [Related]
9. Stepwise management of COPD: What is next after bronchodilation? Miravitlles M; Matsunaga K; Dreher M Ther Adv Respir Dis; 2023; 17():17534666231208630. PubMed ID: 37936381 [TBL] [Abstract][Full Text] [Related]
10. Once daily long-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease. Maqsood U; Ho TN; Palmer K; Eccles FJ; Munavvar M; Wang R; Crossingham I; Evans DJ Cochrane Database Syst Rev; 2019 Mar; 3(3):CD012930. PubMed ID: 30839102 [TBL] [Abstract][Full Text] [Related]
11. Role of Long-Acting Muscarinic Antagonist/Long-Acting β Petite SE Ann Pharmacother; 2017 Aug; 51(8):696-705. PubMed ID: 28410560 [TBL] [Abstract][Full Text] [Related]
14. Inhaled corticosteroids with combination inhaled long-acting beta2-agonists and long-acting muscarinic antagonists for chronic obstructive pulmonary disease. van Geffen WH; Tan DJ; Walters JA; Walters EH Cochrane Database Syst Rev; 2023 Dec; 12(12):CD011600. PubMed ID: 38054551 [TBL] [Abstract][Full Text] [Related]
15. Triple therapy (ICS/LABA/LAMA) in COPD: time for a reappraisal. Vanfleteren L; Fabbri LM; Papi A; Petruzzelli S; Celli B Int J Chron Obstruct Pulmon Dis; 2018; 13():3971-3981. PubMed ID: 30587953 [TBL] [Abstract][Full Text] [Related]
16. A retrospective study to assess clinical characteristics and time to initiation of open-triple therapy among patients with chronic obstructive pulmonary disease, newly established on long-acting mono- or combination therapy. Mapel D; Laliberté F; Roberts MH; Sama SR; Sundaresan D; Pilon D; Lefebvre P; Duh MS; Patel J Int J Chron Obstruct Pulmon Dis; 2017; 12():1825-1836. PubMed ID: 28684905 [TBL] [Abstract][Full Text] [Related]
17. Once-daily long-acting beta₂-agonists/inhaled corticosteroids combined inhalers versus inhaled long-acting muscarinic antagonists for people with chronic obstructive pulmonary disease. Sliwka A; Jankowski M; Gross-Sondej I; Storman M; Nowobilski R; Bala MM Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012355. PubMed ID: 30141826 [TBL] [Abstract][Full Text] [Related]
18. Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta-analysis. Oba Y; Keeney E; Ghatehorde N; Dias S Cochrane Database Syst Rev; 2018 Dec; 12(12):CD012620. PubMed ID: 30521694 [TBL] [Abstract][Full Text] [Related]
19. Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease. Fukuda N; Horita N; Kaneko A; Goto A; Kaneko T; Ota E; Kew KM Cochrane Database Syst Rev; 2023 Jun; 6(6):CD012066. PubMed ID: 37276335 [TBL] [Abstract][Full Text] [Related]
20. Current appraisal of single inhaler triple therapy in COPD. Lipworth B; Kuo CR; Jabbal S Int J Chron Obstruct Pulmon Dis; 2018; 13():3003-3009. PubMed ID: 30319248 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]